Superbug Killer Goes on the Market in Middle East
Health authorities in Saudi Arabia and across the region can now stock up on a revolutionary disinfectant product which combats the SARS-like novel coronavirus which has already killed 24 people in the Kingdom.
There have also been two cases confirmed in the UK during the last three months and a further two cases in France last weekend.
World Health Organization officials visiting Saudi Arabia to consult with the authorities on the latest outbreak said it is likely the new virus could be passed between humans, but only after prolonged, close contact.
The new virus (nCov) can cause coughing, fever and pneumonia. A virus from the same family triggered the outbreak of Severe Acute Respiratory Syndrome (SARS) that swept the world after emerging in Asia and killed 775 people in 2003.
But a revolutionary disinfectant that combats novel coronavirus in just a minute has been developed by a British company and health authorities in the Kingdom and the Gulf can now buy it.
The Noroclear product, which is the first of its type in the world, has gone on sale in the UK in the form of surface wipes, hand wipes and a hand rub.
It is already in use in clinics and hospitals in Germany and Austria.
Strict European standard tests prove that the product – which is free from bleaches and other dangerous chemicals – combats novel coronavirus germ within a minute of contact.
It also kills superbugs including noro virus, MRSA, C Difficile, e.coli, salmonella, listeria and all influenza viruses in less than a minute.
The Noroclear developers, a Cheshire-based company called Arcis-Altos, have put their product through a rigorous European testing regime called EN testing. This underpins the company’s claims for its killing power against superbugs, all human Flu, HIV, swine flu, SARS virus, TB causing bacteria novel coronavirus and norovirus
Other products combat bacteria but are ineffective against not just the novel coronavrius but other human viruses and the spores which cause a wide range of other illnesses.
The company’s chairman, Dr Tim Riley, spent a number of years as chief executive of NHS trusts in the North West of England. He was head of NHS public health policy for the Government in the ‘90s and led the team which developed and set up the National Institute of Clinical Excellence.
He said: “The technology behind the product is revolutionary in its impact because it gives people one product which deals quickly and across the board with superbugs and common globally occurring debilitating infections.
“We are recommending that people use it as a simple precautionary measure in situations where the risk of infection is raised, such as when entering hospital or when traveling.”
Saudi Gazette
